• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020

T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020

by Annie De Groot | Jun 30, 2020

2020 TCWP
Modulation of B. pseudomallei Immune Responses by Human-like T Cell Epitopes

Modulation of B. pseudomallei Immune Responses by Human-like T Cell Epitopes

by Annie De Groot | Nov 20, 2019

Modulation of B. pseudomallei Immune Responses by Human-like T Cell Epitopes
Therapeutic administration of Tregitope-Human Albumin Fusion with Insulin Peptides to promote Antigen-Specific Adaptive Tolerance Induction

Therapeutic administration of Tregitope-Human Albumin Fusion with Insulin Peptides to promote Antigen-Specific Adaptive Tolerance Induction

by Annie De Groot | Nov 12, 2019

Tregitope in T1D Nature Scientific Reports With Suppliment Nov 2019
Ancer-designed CT26 RNA Replicon Neo-epitope Vaccine Induces Multi-functional CD4 and CD8 T Cell Responses

Ancer-designed CT26 RNA Replicon Neo-epitope Vaccine Induces Multi-functional CD4 and CD8 T Cell Responses

by Annie De Groot | Oct 5, 2018

EpiVax_ISV2018_CT26_01Oct18_50Wx36H
HLA Binding Assay Design: Impact of HLA binding motif centering on HLA binding results and T cell response; Relevance to Overlapping Peptide Analysis

HLA Binding Assay Design: Impact of HLA binding motif centering on HLA binding results and T cell response; Relevance to Overlapping Peptide Analysis

by Annie De Groot | Oct 5, 2018

Next Entries »

Recent Posts

  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy 
  • Keeping Tolerance in Focus: Treg Control of ADA Depends on Clinical Context
  • BEBPA Workshop: Streamlining Immunogenicity Assessment of Host Cell Proteins
  • Advancing Immunogenicity Science: EpiVax in 2025 
  • EpiVax Supports Life-Saving Programs Through Partnerships with GAIA Vaccine Foundation and Clínica Esperanza/Hope Clinic

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CMO, Dr. Annie De Groot.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.